The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting

March 6, 2023 updated by: CARLOS ZERRWECK LOPEZ, Hospital General Tlahuac

The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastric Sleeve Surgery

The purpose of this study is to assess the efficacy of Aprepitant + standard antiemetic regimen in reducing postoperative nausea and vomiting after laparoscopic gastric sleeve versus placebo + standard antiemetic regimen

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

After being informed about the study, all patients who provide written informed consent and meet the eligibility requirements will be randomized in a triple-blind manner (participant, evaluator, and investigator) in a 1:1 ratio to Aprepitant (80 or 125 mg) + standard antiemetic regimen (once two hours before surgery) or placebo + standard antiemetic regimen(once two hours before surgery).

The standard antiemetic regimen will be Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg

Study Type

Interventional

Enrollment (Actual)

400

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Mexico City, Mexico
        • Hospital General Tlahuac

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 to 65 years old.
  • Non-smokers.
  • Obesity with BMI > 30 kg/m2.
  • Undergoing laparoscopic gastric sleeve.

Exclusion Criteria:

  • Documented hypersensitivity to any component of the study regimen.
  • Current treatment with: Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole) or Propulsid (cisapride).
  • Allergy to opioid drugs used in the anesthetic protocol.
  • Drug or alcohol abuse.
  • Chronic nausea and vomiting.
  • Previous bariatric procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aprepitant
Aprepitant (80 or 125 mg) + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
Placebo Comparator: Placebo
Placebo + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
Placebo + standard antiemetic regimen, once two hours before surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient's postoperative nausea and vomiting evaluation at 0 hrs (Rhodes index)
Time Frame: 0 postoperative hours
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhodes scale
0 postoperative hours
Patient's postoperative nausea and vomiting evaluation at 6 hrs (Rhodes index)
Time Frame: 6 postoperative hours
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhoades scale
6 postoperative hours
Patient's postoperative nausea and vomiting evaluation at 12 hrs (Rhodes index)
Time Frame: 12 postoperative hours
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhoades scale
12 postoperative hours
Patient's postoperative nausea and vomiting evaluation at 24 hrs (Rhodes index)
Time Frame: 24 postoperative hours
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhoades scale
24 postoperative hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2022

Primary Completion (Actual)

January 1, 2023

Study Completion (Anticipated)

April 1, 2023

Study Registration Dates

First Submitted

February 9, 2023

First Submitted That Met QC Criteria

March 6, 2023

First Posted (Actual)

March 16, 2023

Study Record Updates

Last Update Posted (Actual)

March 16, 2023

Last Update Submitted That Met QC Criteria

March 6, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe